Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Ambrx Biopharma Inc. | 67,313,085 | reported | 20 Apr 2023 | tx 3+5,215,189 |
| MoonLake Immunotherapeutics | 4,927,100 | reported | 30 Jun 2023 | tx 36+8,142,100−2,785,000 |
| BridgeBio Oncology Therapeutics, Inc. | 3,305,470 | reported | 11 Aug 2025 | tx 15+18,031,534−4,662,940 |
| Rain Therapeutics Inc. | 2,776,657 | reported | 27 Apr 2021 | tx 3+2,776,657−2,512,561 |
Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 66 buys in history.
| PROTEOSTASIS THERAPEUTICS, INC. | 2,758,582 | reported | 07 Nov 2016 | tx 4+327,977 |
| Corbus Pharmaceuticals Holdings, Inc. | 2,344,971 | reported | 11 Dec 2025 | tx 25+832,632−30,029 |
| Elevation Oncology, Inc. | 1,983,168 | reported | 29 Jun 2021 | tx 3+2,233,168−1,983,168 |
| BioAge Labs, Inc. | 1,629,529 | reported | 27 Sept 2024 | tx 3+1,629,529−5,263,772 |
| Kezar Life Sciences, Inc. | 1,322,909 | reported | 25 Jun 2018 | tx 5+1,572,909−1,322,909 |
| Tyra Biosciences, Inc. | 1,069,932 | reported | 17 Sept 2021 | tx 3+1,069,932−757,432 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 11 Dec 2025 | SALE | Corbus Pharmaceuticals Holdings, Inc. | 30,029 | 11.46 USD | |
| 11 Aug 2025 | OTHER | BridgeBio Oncology Therapeutics, Inc. | 152,940 | 0.00 USD | |
| 11 Aug 2025 | EXERCISE | BridgeBio Oncology Therapeutics, Inc. | 4,172,126 | — | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 760,496 | 10.72 USD | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 284,571 | — | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 1,762,760 | — | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 1,905,046 | — | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 5,598,425 | 10.72 USD | |
| 11 Aug 2025 | GRANT_AWARD | BridgeBio Oncology Therapeutics, Inc. | 639,110 | 10.72 USD | |
| 11 Aug 2025 | OTHER | BridgeBio Oncology Therapeutics, Inc. | 307,874 | 0.00 USD | deriv |
| 11 Aug 2025 | EXERCISE | BridgeBio Oncology Therapeutics, Inc. | 4,172,126 | — | deriv |
| 11 Jun 2025 | GRANT_AWARD | Biomea Fusion, Inc. | 91,970 | 0.00 USD | deriv |
| 14 Feb 2025 | PURCHASE | Aardvark Therapeutics, Inc. | 187,500 | 16.00 USD | |
| 14 Feb 2025 | CONVERSION | Aardvark Therapeutics, Inc. | 800,189 | — | |
| 14 Feb 2025 | CONVERSION | Aardvark Therapeutics, Inc. | 6,780,810 | — | deriv |
| 08 Feb 2025 | OTHER | BridgeBio Oncology Therapeutics, Inc. | 30,000 | 0.00 USD | deriv |
| 27 Sept 2024 | PURCHASE | BioAge Labs, Inc. | 450,000 | 18.00 USD | |
| 27 Sept 2024 | CONVERSION | BioAge Labs, Inc. | 1,179,529 | — | |
| 27 Sept 2024 | CONVERSION | BioAge Labs, Inc. | 5,263,772 | — | deriv |
| 07 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 90,325 | 39.99 USD | |
| 07 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 10,736 | 39.13 USD | |
| 07 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 46,799 | 37.82 USD | |
| 08 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 24,983 | 42.25 USD | |
| 08 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 61,668 | 44.62 USD | |
| 07 Mar 2024 | PURCHASE | Corbus Pharmaceuticals Holdings, Inc. | 102,140 | 41.23 USD |
2 purchases reported after at least 12 months of silence — most recent on 30 Jun 2020.